Baxter's HemAssist cleared for trauma trial
This article was originally published in Clinica
Executive Summary
Baxter Healthcare's HemAssist has been cleared by the FDA to begin a Phase III trial in the US. The purpose of the trial is to investigate the effect of the liquid on survival in patients suffering severe trauma. HemAssist is an oxygen-carrying liquid which is used as a temporary substitute for lost blood. It restores blood pressure and increases oxygen delivery in patients suffering from blood loss and shock caused by severe trauma.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.